Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study
Open Access
- 1 January 2013
- journal article
- Published by Hindawi Limited in International Journal of Hypertension
- Vol. 2013, 1-9
- https://doi.org/10.1155/2013/541689
Abstract
This study was designed to assess the effects of moxonidine on blood pressure and aspects of the metabolic syndrome in racially diverse population of patients encountered in routine medical practice. Physicians collected data on a minimum of three consecutive patients with uncontrolled essential hypertension and criteria for metabolic syndrome, eligible to receive moxonidine (0.2–0.4 mg once daily) for 6 months, either as monotherapy or as adjunct therapy to current antihypertensive treatment. Systolic and diastolic blood pressure (BP) declined by an average of mmHg and mmHg, respectively. BP responder rates defined as attaining BP < 140/90 mmHg were significantly () and substantially higher among younger patients, nonpostmenopausal women, and patients receiving monotherapy. While potentially relevant improvements in the entire cohort were observed in regard to body weight ( kg), fasting plasma glucose (from 6.8 to 6.2 mmol/L), and triglycerides (2.4 to 2.0 mmol/L), statistically significant changes in metabolic parameters could only be detected in subgroup analyses. Moxonidine therapy reduced blood pressure and improved rates of blood pressure control in this group of patients. While the observed trend towards improvement in various metabolic parameters merits further investigation, the overall effect of moxonidine treatment is consistent with a reduction of total cardiovascular risk in this hypertensive metabolic syndrome cohort.
Keywords
Funding Information
- Abbott Products Operations AG
This publication has 31 references indexed in Scilit:
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsThe New England Journal of Medicine, 2010
- Sympathetic Nervous System Activity Is Associated With Obesity-Induced Subclinical Organ Damage in Young AdultsHypertension, 2010
- Increased Sympathetic and Decreased Parasympathetic Activity Rather Than Changes in Hypothalamic-Pituitary-Adrenal Axis Activity Is Associated with Metabolic AbnormalitiesJournal of Clinical Endocrinology & Metabolism, 2010
- Blood pressure control and components of the metabolic syndrome: the GOOD surveyCardiovascular Diabetology, 2009
- Metabolic Syndrome Affects Cardiovascular Risk Profile and Response to Treatment in Hypertensive Postmenopausal WomenHypertension, 2008
- Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease surveyJournal of Hypertension, 2008
- Menopause and the Metabolic SyndromeThe Study of Women's Health Across the NationJAMA Internal Medicine, 2008
- Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in womenMetabolism, 2008
- Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trialClinical Therapeutics, 2007
- Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metforminDiabetes, Obesity and Metabolism, 2006